Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HERNAN A SALAZAR

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1538220892
CMS profile
919244
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$713.29

23 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $359.25 3
Food and Beverage $354.04 20

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $671.70 21
Novartis Pharmaceuticals Corporation $41.59 2

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HERNAN A SALAZAR

NPI 1538220892 · CMS profile ID 919244

Allopathic & Osteopathic Physicians / Internal Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538220892?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538220892?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538220892?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1538220892?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

23 matching records · $713.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 23 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–23 of 23.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $288.6009/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657865861 CMS
Eli Lilly and Company $4.6209/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709007629 CMS
Eli Lilly and Company $33.2609/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008115 CMS
Eli Lilly and Company $11.0909/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008833 CMS
Eli Lilly and Company $44.3409/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008835 CMS
Eli Lilly and Company $25.8709/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008837 CMS
Eli Lilly and Company $3.3309/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008839 CMS
Eli Lilly and Company $23.6409/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009169 CMS
Eli Lilly and Company $8.3209/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009171 CMS
Eli Lilly and Company $10.9809/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009173 CMS
Eli Lilly and Company $18.4809/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009175 CMS
Eli Lilly and Company $4.4309/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009177 CMS
Eli Lilly and Company $8.2509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009343 CMS
Eli Lilly and Company $59.6709/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009345 CMS
Eli Lilly and Company $5.9109/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009347 CMS
Eli Lilly and Company $1.8509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009653 CMS
Eli Lilly and Company $2.0609/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009655 CMS
Eli Lilly and Company $10.3509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009833 CMS
Eli Lilly and Company $2.3609/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009835 CMS
Eli Lilly and Company $103.4709/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709010581 CMS
Eli Lilly and Company $0.8209/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709010583 CMS
Novartis Pharmaceuticals Corporation $20.5008/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660037539 CMS
Novartis Pharmaceuticals Corporation $21.0904/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660037537 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $713.29 23
PY2020 $397.53 3
PY2023 $727.75 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $189,942.29 38
PY2024 Principal investigator $116,310.00 16
PY2023 Recipient $291.00 1
PY2023 Principal investigator $1,683,804.34 55
PY2022 Recipient $1,491.00 2
PY2022 Principal investigator $4,307,067.33 117
PY2021 Recipient $201.98 1
PY2021 Principal investigator $8,685,200.41 155
PY2020 Recipient $145.50 1
PY2020 Principal investigator $2,390,117.44 47
PY2019 Recipient $705.39 1
PY2019 Principal investigator $1,142,050.05 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $5,404.10 11/05/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760357
Principal investigator 1 Boehringer Ingelheim International GmbH $1,043.90 10/03/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760355
Principal investigator 1 Boehringer Ingelheim International GmbH $4,022.20 09/24/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760349
Principal investigator 1 Boehringer Ingelheim International GmbH $14,020.50 09/15/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760351
Principal investigator 1 Boehringer Ingelheim International GmbH $4,022.20 09/01/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760347
Principal investigator 1 Boehringer Ingelheim International GmbH $14,357.20 09/01/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760353
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 08/26/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760341
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 08/26/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760343
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 07/28/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760339
Principal investigator 1 Boehringer Ingelheim International GmbH $207.38 07/22/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760329
Principal investigator 1 Boehringer Ingelheim International GmbH $72.00 07/22/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760331
Principal investigator 1 Boehringer Ingelheim International GmbH $2.92 07/22/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760333
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 07/22/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760335
Principal investigator 1 Boehringer Ingelheim International GmbH $11.32 07/22/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760337
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760327
Principal investigator 1 Boehringer Ingelheim International GmbH $1,248.00 06/16/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760323
Principal investigator 1 Boehringer Ingelheim International GmbH $4,500.00 06/16/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760325
Principal investigator 1 Boehringer Ingelheim International GmbH $4,500.00 06/12/2025 Non-covered Recipient Entity
Hasresearch
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760369
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 03/25/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760313
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760315
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 03/25/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760317
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 03/25/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760319
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 03/25/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760321
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 03/25/2025 Non-covered Recipient Entity
Hasresearch
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760359
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
Hasresearch
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760361
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 03/25/2025 Non-covered Recipient Entity
Hasresearch
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760363
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 03/25/2025 Non-covered Recipient Entity
Hasresearch
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760365
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 03/25/2025 Non-covered Recipient Entity
Hasresearch
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760367
Principal investigator 1 Boehringer Ingelheim International GmbH $66,960.00 03/12/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760345
Principal investigator 1 Boehringer Ingelheim International GmbH $66,960.00 03/12/2025 Non-covered Recipient Entity
Hasresearch
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760371
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 02/28/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760297
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 02/28/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760299
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 02/28/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760301
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 02/28/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760303
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/28/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760305
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/28/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760307
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 02/28/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760309
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 02/28/2025 Non-covered Recipient Entity
Hasresearch
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760311